End to own name defence for corporate names

In Insights, Uncategorized

16 March, 2016

The new Regulation (EU) 2015/2424 amending Council Regulation 207/2009/EC on the Community Trade Mark (CTM) will enter into force from 23 March 2016


The use of another’s registered trade mark without consent as a trade name or company name will now specifically be deemed infringing use. Using a sign as a trade name or a company name can infringe a CTM.

Defendants in infringement proceedings are currently able to rely on the “own name” defence to infringement, whether or not the defendant is a natural or legal person, i.e. whether or not the name used is a personal or company name.

The new Regulation expressly limits the defence to use of personal names only. Legal entities will no longer be able to rely on the fact that they are using their company name. With the new Regulation in place, ASOS (see Maier v ASOS plc) would not have benefitted from the ‘own name’ defence.

In view of that using a registered trademark as a trade or company name (or part of such) now is a specific infringement, it is more important than ever that businesses looking to expand into the EU cannot rely on their trade or company name. They should conduct the necessary clearance searches to ensure that their trade or company name will not infringe any third party rights. If the clearance search indicates that the dominant part of the company name does not infringe any third party rights, the company should file an EU trademark application. The other side of the coin, trademark owners that do not already subscribe to a company name watching service may consider doing so.

Niclas Dahlberg, Attorney at Law

You may also be interested in:

Companies with IP generate at least 23.8% more revenue according to latest EU report

The report ‘The Intellectual Property Rights and Firm Performance in the European Union’ was published last month and analyses

Read more...

European Commission reports show misuse of divisionals can in itself contravene EU law

In November last year, I was interviewed about the European Commission’s €462.6 million fine against pharmaceutical giant Teva and

Read more...

IP Enforcement Strategies: Combating Counterfeiting in Southeast Asia and China

Counterfeiting remains among the most significant threats to intellectual property rights globally, particularly in Southeast Asia and China. These

Read more...

Mobile Sliding Menu